HERVolution Therapeutics, a Denmark-based biotech applying immunotherapy to metabolic disease, has secured an exclusive license from the University of Copenhagen covering HERV-targeting immune therapy technology for weight gain control — a deal that extends the company's platform beyond oncology into one of the largest therapeutic areas in medicine. The agreement formalizes a research collaboration between HERVolution and university scientists, with preclinical data presented simultaneously at the American Diabetes Association 2026 Scientific Sessions. Financial terms were not disclosed.
The transaction is notable because it positions a preclinical immunotherapy mechanism — directing the immune system against human endogenous retrovirus (HERV) antigens — as a potential approach to metabolic disease, an area currently dominated by GLP-1 and GIP receptor agonists. HERVolution, which raised USD 11.7 million in a Series A in December 2024 led by Serum Institute of India with participation from the European Innovation Council Fund, had previously focused its platform on oncology through its lead program IPT-001.
Under the agreement, HERVolution receives exclusive rights to develop, manufacture, and commercialize products in the licensed field. The University of Copenhagen retains ownership of the underlying intellectual property, consistent with standard academic licensing structures. No option mechanics, co-development obligations, or geographic restrictions were disclosed.
The licensed technology arises from collaborative preclinical studies in which HERVolution's platform was applied to engage endogenous retroviral targets in models of weight gain and metabolic disease. Data presented at the ADA meeting demonstrated control of weight gain in a high-fat diet context combined with underlying metabolic disease, along with reversal of type 2 diabetes markers and reductions in "inflammaging" biomarkers — a composite measure of chronic low-grade inflammation associated with aging. No drug candidate has been formally named or coded for this metabolic program.
HERVolution's platform is built around the observation that HERV sequences — ancient viral remnants comprising roughly 8% of the human genome — become aberrantly re-expressed under conditions of aging, cancer, and metabolic disease. The company has developed proprietary engineering approaches to modify HERV antigens so that the immune system, which normally treats them as self, can mount targeted responses against HERV-expressing cells. In metabolic disease, the company describes HERV-K expression as linked to cellular senescence and insulin resistance.